Trial Profile
A Phase II, open-label, rollover trial to evaluate the safety and immunogenicity of one or two boosting doses of Comirnaty or one dose of BNT162b2s01 in BNT162-01 trial subjects, or two boosting doses of Comirnaty in BNT162-04 trial subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors BioNTech
- 20 Sep 2022 Status changed from active, no longer recruiting to completed.
- 25 Aug 2022 Planned End Date changed from 15 Sep 2022 to 16 Sep 2022.
- 27 Jul 2022 Planned End Date changed from 1 Oct 2022 to 15 Sep 2022.